Ron Guido is Chief Executive Officer at Brooklyn ImmunoTherapeutics and was formerly Executive Vice President Regulatory Affairs and Quality Systems. He was previously Senior VP Regulatory Affairs and Quality Systems at IRX Therapeutics. Prior to joining the company in January 2017, Mr. Guido was Senior Vice-President Global Regulatory Affairs and Chief Compliance Officer for Veloxis Pharmaceuticals, Denmark. Mr. Guido was previously Senior Director and Therapeutic Area Head for Cardiovascular Medicine – Worldwide Regulatory Strategy for Pfizer. Ron Guido has held senior roles areas of preclinical screening, clinical research, regulatory affairs, product development and quality systems with Retrophin, V.I. Technologies/ Precision Pharma Services, Whitehall-Robins Healthcare, Fresenius Pharma USA, and Wyeth-Ayerst Laboratories. These responsibilities have included international and domestic regulatory affairs development programs encompassing drugs, devices, biologics, and nutritionals. Mr. Guido holds an M.S. in Technical Communications from the Polytechnic University, New York, and an MSc Pharmaceutical Medicine from Hibernia College, Dublin. He is currently Lecturer in Biology, in the Masters of Biotechnology Program at Columbia University of the City of New York.
Monil Shah, PharmD, MBA, is Senior Advisor, Clinical Development At Brooklyn ImmunoTherapeutics. Previously, he was Chief Operating Officer at IRX Therpeutics and has over 18 years of pharmaceutical and biotechnology industry experience in oncology drug development. Prior to joining IRX Therapeutics, Dr. Shah was the Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb. Dr. Shah was Head of Clinical Operations and Development at Ventrus Biosciences prior to its merger with Assembly Biosciences. Prior to Ventrus, Dr. Shah led the solid tumor development programs and led the clinical portfolio and strategic planning function at Celgene Corporation. He led the Oncology Development and Operations activities at Fibrogen and Novacea. Dr. Shah began his career at Novartis in the Oncology Early Development Group leading clinical trials prior to joining the Medical Sciences Group at Amgen. Dr. Shah received his BS and PharmD degrees from Rutgers, The State University of New Jersey and his MBA from Florida Institute of Technology.
Lynn Sadowski Mason is the Executive Vice President Clinical Operations at Brooklyn ImmunoTherapeutics. Prior to joining Brooklyn Immunotherapeutics, she was the Head of Operations at IRX Therapeutics. Lynn has 19 years of pharmaceutical and biotechnology industry experience in clinical operations. For the last 13 years, she has been working to operationalize ImmunoOncology studies around the globe, including working on critical studies with Yervoy, Opdivo, and Elotuzumab. Lynn spent 12 years at Bristol Myers Squibb (BMS). In her most recent role at BMS, Lynn was the Connecticut site head for Global Clinical Operations and Strategy, where she led a team of up to 50 clinical operations staff. Prior to that, Lynn spent three years on assignment in Europe where she oversaw clinical operations activities in Romania, Czech Republic, Hungary and Turkey. Prior to BMS, Lynn worked for various small pharmaceutical companies and Contract Research Organizations. Lynn received her BS in Biology from Indiana University, and her Masters Degree in Drug and Regulatory Affairs from Massachusetts College of Pharmacy and Health Sciences.